How to buy Nkarta stock | $24.35

Nkarta, Inc is a biotechnology business based in the US. Nkarta shares (NKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Nkarta employs 107 staff and has a trailing 12-month revenue of around 0.00.

Nkarta stock price (NASDAQ: NKTX)

Use our graph to track the performance of NKTX stocks over time.

Nkarta shares at a glance

• Key figures

Information last updated 2021-07-01.

Latest market close	$24.35
52-week range	$22.46 - $79.16
50-day moving average	$26.43
200-day moving average	$40.93
Wall St. target price	$77.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.88

Buy Nkarta shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Nkarta stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Nkarta, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nkarta price performance over time

Historical closes compared with the close of $24.35 from 2021-05-28

1 week (2021-06-29)	-17.96%
1 month (2021-06-02)	-3.45%
3 months (2021-04-05)	-27.36%
6 months (2021-01-05)	-56.89%

1 year (2020-07-02)	N/A
2 years (2019-07-02)	N/A
3 years (2018-07-02)	N/A
5 years (2016-07-02)	N/A

Nkarta financials

Revenue TTM	$385
Gross profit TTM	$-36,220,000
Return on assets TTM	-20.99%
Return on equity TTM	-61.44%
Profit margin	0%
Book value	N/A
Market capitalisation	$1 billion

TTM: trailing 12 months

Shorting Nkarta shares

There are currently 2.0 million Nkarta shares held short by investors – that's known as Nkarta's "short interest". This figure is 7.1% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Nkarta shares can be evaluated.

Nkarta's "short interest ratio" (SIR)

Nkarta's "short interest ratio" (SIR) is the quantity of Nkarta shares currently shorted divided by the average quantity of Nkarta shares traded daily (recently around 207100.94537815). Nkarta's SIR currently stands at 9.52. In other words for every 100,000 Nkarta shares traded daily on the market, roughly 9520 shares are currently held short.

However Nkarta's short interest can also be evaluated against the total number of Nkarta shares, or, against the total number of tradable Nkarta shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nkarta's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Nkarta shares in existence, roughly 60 shares are currently held short) or 0.1428% of the tradable shares (for every 100,000 tradable Nkarta shares, roughly 143 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nkarta.

Find out more about how you can short Nkarta stock.

Nkarta share dividends

We're not expecting Nkarta to pay a dividend over the next 12 months.

Nkarta overview

Nkarta, Inc. , a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California. .

Frequently asked questions

What percentage of Nkarta is owned by insiders or institutions?
Currently 10.702% of Nkarta shares are held by insiders and 86.852% by institutions. How many people work for Nkarta?
Latest data suggests 107 work at Nkarta. When does the fiscal year end for Nkarta?
Nkarta's fiscal year ends in December. Where is Nkarta based?
Nkarta's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Nkarta's ISIN number?
Nkarta's international securities identification number is: US65487U1088